secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001171843-25-005406
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences Q2 2025 net loss $44.2M, including $31.25M litigation reserve; shifts focus to TSC epilepsy
--------------------------------------------------------------------------------

- Net loss $44.2M ($0.92 per share) vs net income $6.2M in Q2 2024.
- Recorded $31.25M estimated loss contingency for securities litigation settlement.
- Alzheimer's program phased out; new focus on simufilam for TSC-related epilepsy - PoC study expected H1 2026.
- Cash $112.4M at June 30, 2025; H2 2025 net cash use $47-51M including litigation reserve.
- Appointed Dr. Hulihan (CMO), Dr. Bordey (SVP Neuroscience), Dr. Moore (SVP Clin Dev).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184325005406/0001171843-25-005406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184325005406/f8k_081425.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer